Adherence to nCPAP in patients with coronary disease and sleep apnea without sleepiness  by Sampol, Gabriel et al.
ARTICLE IN PRESS
Respiratory Medicine (2007) 101, 461–4660954-6111/$ - see fro
doi:10.1016/j.rmed.
$Supported in pa
C03/11).
Corresponding au
E-mail address: gAdherence to nCPAP in patients with coronary disease
and sleep apnea without sleepiness$
Gabriel Sampola,, Gloria Rode´sa, Odile Romerob,
Marı´a Jose´ Juradob, Patricia LloberesaaRespiratory Department, Hospital Universitari Vall d0Hebron, Universitat Auto`noma de Barcelona, Barcelona, Spain
bNeurophysiology Department, Hospital Universitari Vall d0Hebron, Universitat Auto`noma de Barcelona, Barcelona, Spain
Received 17 February 2006; accepted 8 July 2006KEYWORDS
Sleep apnea;
Coronary disease;
Nasal continuous
positive airway
pressure;
Sleepnt matter & 2006
2006.07.007
rt by Red Respira (
thor. Tel.: +34 93 2
sampol@vhebron.Summary
Many patients with obstructive sleep apnea (OSA) do not have sleepiness and adherence to
nasal continuous positive airway pressure (nCPAP) is unknown when this treatment is
primarily recommended for a cardiovascular concern. The aim of this study was to
determine the adherence to nCPAP in patients with coronary artery disease (CAD) and OSA
without sleepiness.
nCPAP was recommended in 75 patients with CAD and OSA, 29 without and 46 with
sleepiness. The daily use of nCPAP and changes in sleepiness (Epworth Sleepiness Scale), in
other OSA symptoms and in SF-36 quality-of-life questionnaires were evaluated at 1 yr of
follow-up.
Sixty-seven patients (89%) were still using nCPAP at the end of follow-up. The absence of
sleepiness at diagnosis did not imply a greater number of nCPAP refusals and nCPAP
adherence was similar in both groups, 5.1 (1.5) h in patients without versus 5.4 (1.6) h in
patients with sleepiness. In patients with sleepiness at diagnosis, the use of nCPAP was
associated with reduced sleepiness and improvement in the OSA symptoms and quality-of-
life questionnaires; in contrast, only the symptoms questionnaire improved in patients
without sleepiness.
In conclusion, in our experience adherence to nCPAP treatment in patients with CAD and
OSA is not influenced by the absence of sleepiness.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
Instituto Carlos III. FIS.RTYC-
746157; fax: +34 93 2746083.
net (G. Sampol).1. Introduction
Obstructive sleep apnea (OSA) is a high-prevalence disorder1
characterized by repeated upper airway obstruction during
sleep. These obstructive episodes produce desaturations
and sleep fragmentation and lead to diurnal sleepiness, the
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treatment criterion. Nasal continuous positive airway
pressure (nCPAP) constitutes the standard treatment of
OSA2 and controlled studies have shown it to be associated
with reduced sleepiness and improved quality of life in these
patients.3,4
However, population studies have shown that many OSA
patients, even some with very frequent apneic episodes, do
not present sleepiness.1,5 Similarly, it has been acknowl-
edged that OSA is associated with cardiovascular disease,
including hypertension, coronary artery disease (CAD), heart
failure, arrhythmias and cerebrovascular disease6 and that
its treatment may lead to lower cardiovascular morbidity7
and mortality.8,9 In CAD patients, it has been shown that the
coexistence of OSA may cause nocturnal angina and ST-
segment depression10 and is associated with worse long-
term prognosis11 and that nCPAP improves nocturnal
ischemic episodes.12
For these reasons, the number of patients with cardio-
vascular disease and suspected OSA without sleepiness
referred to sleep laboratories for vascular concern has
increased. When OSA is confirmed in these patients, nCPAP
has been recommended with the aim of reducing their
cardiovascular risk.13,14 Since OSA is normally a life-long
condition, the effectiveness of nCPAP depends essentially on
the long-term adherence of the patient to the treatment. In
sleepy OSA patients, several studies have shown this
adherence to be related to the patients’ degree of
sleepiness at diagnosis15–17 and its improvement with
nCPAP,18,19 and contrarily the main cause of abandonment
is the absence of perceived benefit. By contrast, adherence
to treatment when prescribed in non-sleepy patients for
cardiovascular reasons has not been studied, with the
previous considerations pointing towards poor treatment
compliance.
The aim of this study was to ascertain whether nCPAP is a
viable therapeutic option in patients with CAD and OSA
without sleepiness. To this end, we compared long-term
adherence to nCPAP in a group of these patients with that of
a control group of patients with CAD and OSA with
sleepiness.2. Material and methods
Seven hundred and sixty consecutive patients with sus-
pected OSA were studied at our sleep laboratory over a
period of 4 months (January–April, 2004); of these, all
patients who fulfilled the inclusion criteria of a diagnosis of
CAD (angina pectoris or myocardial infarction) confirmed by
coronary arteriography or stress testing and having X10
apneas or hypopneas per hour of sleep were selected.
Exclusion criteria were previous diagnosis of OSA (n ¼ 2),
unavailable coronary arteriography or stress testing reports
(n ¼ 5), shift work (n ¼ 1) or any other condition that could
account for the patient sleepiness (n ¼ 5, use of sedatives in
all). The study was approved by the Ethics Committee of our
hospital.
The seventy-five eligible patients were controlled peri-
odically by a cardiologist, who was the referring physician in
21; the rest were referred by a general practitioner
(n ¼ 36), pneumologist (n ¼ 9) or another specialist (n ¼ 9).2.1. Procedures
Patients were evaluated by an expert in sleep medicine. A
questionnaire on smoking history, alcohol consumption,
coexisting diseases, quality of life, medication, sleep habits,
daytime sleepiness and other OSA symptoms was adminis-
tered to each patient.
Daytime sleepiness was evaluated by the Epworth Sleepi-
ness Scale (ESS),20 using its cross-culturally valid Spanish
version,21 and the International Classification of Sleep
Disorders.22 A patient was considered not to present
sleepiness if his/her ESS score was o10 and there was no
or mild daytime sleepiness according to the International
Classification of Sleep Disorders.
The patient and, when possible, his/her bed partner,
were questioned on 7 items to assess the presence of other
OSA symptoms: snoring, observed apneas, choking awaken-
ings, nocturia, feeling of non-refreshing sleep and head-
aches or dry mouth on awakening in the morning. Possible
answers were scored as follows: never, rarely ¼ 0, some-
times ¼ 1, frequently, always ¼ 2; a final symptom score
was obtained for each patient by totaling the points of each
item, oscillating between 0 (absence of symptoms) and 14
(maximum symptomatic patient). Quality of life was
evaluated by the Medical Outcomes Study Short Form-36
questionnaire (SF-36), a commonly used instrument for
evaluating general health and functional status23,24 widely
employed in many chronic processes.25 The SF-36 yields
eight domain scores (physical function, physical role,
emotional role, pain, general health, social function,
vitality and health status) and two summary measurements
(mental component summary and physical component
summary). The domain scores are transformed onto a scale
from 0 (worst possible health status) to 100 (best possible
health status). The two summary measurements have a
mean value of 50 and a standard deviation of 10 in the
general Spanish population. Comorbidity was assessed using
the Charlson weighted index,26 a normalized scale of 15
chronic diseases.
A full polysomnography (Compumedics E Series, Abbots-
ford, Australia) that included recording of oronasal flow
(thermistor), thoracoabdominal movements (strain gauges),
electrocardiography, submental electromyography, bilateral
electrooculography, electroencephalography (C4-A1, C3-A2),
oxyhemoglobin saturation (finger pulse oxymeter), body
position, leg movements and snoring was used in 49
patients. A respiratory polygraphy with a device validated
with full polysomnography (Sibel, Barcelona, Spain)27 which
records nasal airflow (thermistors), respiratory effort (chest
and abdominal gauges), snoring (microphone), body position
and finger pulse-oximetry was used in 26 patients. Patient
assignment to full polysomnography or respiratory polygra-
phy depended only on device availability in our sleep unit.
All sleep studies were reviewed manually by an expert
scorer blinded to the study. An apnea was defined as
cessation of airflow with a duration of at least 10 s.
Differentiation was made between obstructive and central
apneas according to the respiratory effort channels (pre-
sence or absence of thoracoabdominal movement). Hypop-
nea was defined as a450% reduction in themistor tracing
with a duration of at least 10 s associated with a cyclical dip
in SaO243%. The apnea–hypopnea index (AHI) was defined
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by the total sleep time, in patients studied by complete
polysomnography, or by time in bed in those assessed with a
limited sleep study.
Following the diagnosis of OSA, the patients received an
explanation of the treatment with nCPAP. This treatment
was offered as a means of controlling the symptoms with
collateral improvement in the prognosis of CAD. All patients
agreed to undergo an nCPAP titration study by full
polysomnography in which the effective nCPAP pressure
required to abolish apneas, hypopneas, snoring and oxygen
desaturations according to standard criteria was deter-
mined.28 After the study, patients received written informa-
tion on general measures in OSA treatment and were
prescribed nCPAP, provided free by our National Health
Service. Following the start of the treatment, patients were
seen at 1,3, 6 and 12 months to encourage patient
adherence and solve any problem associated with nCPAP
use. At the last visit, the ESS, the symptoms and SF-36
questionnaires were administered again and compliance
with nCPAP was assessed by the time counter incorporated
in the device by dividing the difference of hours of use since
the first visit by the number of days elapsed. At this visit the
patient was also asked about his/her willingness to continue
the treatment and, if so, he/she was asked whether the
main reason for continuing with nCPAP was the improvement
in symptoms or the advice received regarding the benefit on
CAD.2.2. Analysis
The main variable of our study was the number of hours/
night of adherence to nCPAP determined by the built in timeTable 1 Characteristics of patients who completed follow-up.
OSA without sleepine
Age (years) 62.8 (10.6)
Sex (male/female) 21/4
BMI (kg/m2) 30.1 (1.5)
CADy (angina/myocardial infarction) 13/12
Charlson’s comorbidity index 2.0 (1.4)
Usual hours of sleep (h/night) 7.9 (0.9)
Years of CAD evolution 3.4 (3.8)
PSG/RPz 17/8
AHIy (events/hour) 55.4 (21.6)
SaO2
z mean 91.2 (3.1)
SaO2, minimum 72.8 (10.0)
CT90 25.3 (26.3)
Desaturation index (n/hour)yy 59.8 (23.8)
NCPAPzz (cmH2O) 8.0 (1.4)
BMI: body mass index.
yCAD: coronary artery disease.
zPSG: full polysomnography; RP: respiratory polygraphy.
yAHI: apnea-hypopnea index.
zSaO2: arterial oxygen saturation.
CT90: percentage of sleep time with arterial oxygen saturation
yyDesaturation index: desaturations 43%/hour.
zznCPAP: effective nasal continuous airway pressure.counter. The study was powered to detect a difference of 1 h
between patients with and without sleepiness. Assuming,
according to our experience, adherence in patients with OSA
and sleepiness of 5.5 (1.0) h/night, 22 patients in each group
were required to complete the study if an a error of 0.5 and
a b error of 0.1 were assumed.
Statistical analysis was made with the SPSS statistical
package, version 11.0. Data are reported as mean (SD).
Differences between means were analyzed by the paired
and unpaired Student’s t-test according to requirements.
Qualitative variables were analyzed using the w2 or Fisher’s
exact tests. Statistical significance was assumed at Po0.05.
The clinical significance of the changes experienced in the
ESS, symptoms questionnaire and the eight subscores and
the two summary components of the SF-36 were calculated
using the effect size (score difference/baseline score SD)29
which was conventionally interpreted as representing
clinically small (0.20 SD units), moderate (0.50 SD units) or
large (0.8 or more SD units) differences.303. Results
Seven patients, 4 with and 3 without sleepiness at diagnosis,
refused nCPAP. All refusals of nCPAP occurred immediately
after the titration study (n ¼ 3) or during the first month of
treatment (n ¼ 4). One patient without sleepiness at
diagnosis died during follow-up. Characteristics of the 67
patients, 25 without and 42 with sleepiness, who completed
the follow-up are detailed in Table 1. Both groups were
similar in age, sex, body mass index, CAD, comorbidity and
usual hours of sleep. Patients without sleepiness presented
fewer years of CAD evolution since their initial diagnosis.
The type of sleep study, OSA severity, assessed by AHI, meanss (n ¼ 25) OSA with sleepiness (n ¼ 42) P
67.3 (8.3) ns
34/8 ns
30.2 (1.8) ns
17/25 ns
2.0 (1.5) ns
7.7 (0.8) ns
5.8 (5.0) 0.046
28/14 ns
54.6 (22.1) ns
89.5 (5.9) ns
70 (10.8) ns
30.1 (31.9) ns
58.3 (22.5) ns
8.6 (1.9) ns
o90%.
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G. Sampol et al.464SaO2, minimum SaO2 and time with SaO2o90%, were also
similar in both groups, as was the nCPAP pressure required to
abolish the obstructive events. No differences were ob-
served in age, sex, comorbidity, years of CAD evolution, AHI,
mean and minimum SaO2 and effective nCPAP pressure
among patients studied either by full polysomnography or
respiratory polygraphy.
Nasal CPAP adherence measured at the last visit was not
influenced by the presence of sleepiness at diagnosis: 5.1
(1.5) h in the group without versus 5.4 (1.6.) h in the group
with sleepiness (p:n.s.). At baseline, patients with sleepi-
ness were more symptomatic and presented lower scores on
the SF-36 subscales of physical function, emotional role,
mental health, vitality and mental component score. At 1 yr
of follow-up, no differences were observed in symptoms,
sleepiness or quality of life (Table 2). This was due to a
greater improvement in these variables in the group with
sleepiness at diagnosis. In general, the improvements were
slight or moderate. Large differences in the effect size were
found only in the symptoms score in both groups and, in the
group of patients with sleepiness at diagnosis, in the ESS
(Fig. 1) and the subscales of vitality and mental health of
the SF-36.
Fourteen (56%) patients of the group without and 21 (50%)
of the group with sleepiness reported some adverse effect
related to the use of nCPAP during follow-up (p:n.s.). These
effects were minor in all cases (19 mask problems, 14 dry
mouth or rhinorrhea, 7 sleep disruption by noise) and did not
lead to abandonment of treatment in any case. At the end of
follow-up, only 1 patient without sleepiness at diagnosis,
with a mean nCPAP use of 2.7 h/night, opted to abandon the
treatment. The main reason in the rest for continuing
treatment was their belief in the beneficial effect on their
CAD, which was argued by 16 (64%) patients without and 24
(53%) with sleepiness (p:n.s.); the remaining patients
considered improvement in symptoms present at diagnosis
to be the main reason for continuing with nCPAP.Ta
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n4. Discussion
In the present study, patients with CAD and OSA presented
good long-term adherence to nCPAP, which was not
influenced by the absence of sleepiness at OSA diagnosis.
As described previously,3,31 the use of nCPAP in somnolent
patients implied improvement in sleepiness and quality of
life, particularly in the subscores of vitality and mental
health and, in contrast, no significant changes in these
variables were observed in patients without sleepiness.
Our results contrast with those of previous works that
related good adherence to nCPAP to sleepiness.15–19 Various
aspects may be associated with acceptance of the treatment
by our non-somnolent patients. First, we recommended
nCPAP treatment not only as a means of controlling
symptoms but also as part of their CAD treatment, and
acceptance of this recommendation was the main reason at
the end of follow-up, even among those with sleepiness at
diagnosis, for their willingness to continue the treatment.
Second, we considered the use of a generic questionnaire
such as the SF-36 to be the best option for evaluating the
impact of treatment on quality of life in a population with
significant comorbidity. However, this generic questionnaire
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Figure 1 Changes in Epworth Sleepiness Scale (ESS) and
symptom scores with nCPAP at 1 yr of follow-up.
nCPAP in sleep apnea and coronary disease 465may not have been sufficiently sensitive to the clinical
change associated with the improvement detected in OSA
symptoms. This improvement, though smaller than that
observed in somnolent patients, was considered to be the
main reason for continuing treatment by a third of patients
without sleepiness. Third, our non-somnolent patients were
referred to the sleep clinic basically for being severe snorers
with apneas observed by the bed partner. The sleep study
showed a high AHI, which has been suggested as a predictor
of adherence to nCPAP15,32 and the use of nCPAP was
associated with an improvement in their symptoms (Fig. 1).
Our patients are not necessarily representative of all
patients with CAD; we do not know what the acceptance
of nCPAP by CAD patients would be if an active search of OSA
were carried out among them, which would probably detect
patients with fewer symptoms and a lower AHI than those
found in our study.
Sleepiness was not measured objectively in our patients.
However, adherence to CPAP has been basically related to
subjective sleepiness measurements, and this subjective
perception is the main reason for recommending nCPAP
treatment in clinical practice. Furthermore, the criteria
adopted to rule out significant sleepiness were restrictive,
and the ESS score in our non-sleepy patients was similar to
that reported in simple snorers20 and did not change
significantly with nCPAP treatment.
Although the relationship between CAD and OSA remains
poorly understood, it seems plausible that the presence of a
high number of apneas and severe desaturations, such as
those in our patients, may adversely affect the prognosis of
their CAD, regardless of the presence or not of sleepiness.
Treatment with nCPAP reverses nocturnal hypoxemia,
changes in intrathoracic pressures and sleep fragmentation
associated with apnea and hypopnea episodes. It is the only
OSA treatment available that has proved to reverse various
intermediate mechanisms derived from these alterations
that have been proposed in the increase in cardiovascular
risk of these patients such as sympathetic activation,33
oxidative stress,34 endothelial dysfunction,35 inflamma-
tion,36 hypercoagulability37 and metabolic disregulation.38
In accordance with these findings, a recent study39 in
patients with CAD and OSA showed that treatment with
nCPAP led, in the long term, to a reduced number of newcardiovascular events, defined as cardiovascular death,
acute coronary syndrome, hospitalization for heart failure
or need for coronary revascularization. However, those
authors made no mention of the presence of sleepiness or
other OSA symptoms, and the majority of their patients
received no OSA treatment. The reason for not treating
them was primarily the concern that nCPAP might adversely
affect the patients’ quality of life. This leads us to believe
that only sleepy patients were treated. By contrast, this
concern was not confirmed in our patients with CAD and OSA
without sleepiness. While awaiting further studies on the
relationship between CAD and OSA, since many patients
with OSA do not present significant sleepiness, we consider
our results to be significant for the clinical management of
these patients.
In summary, we found good long-term adherence to nCPAP
in patients with CAD and OSA, regardless of the presence or
not of sleepiness. These results show that the recommenda-
tion of nCPAP can be considered in secondary CAD
prophylaxis protocols in patients with OSA and no associated
sleepiness.Acknowledgment
The authors thank Christine O0Hara for manuscript correction.References
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